Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3CNS 3Sarcoma 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1Myeloid 1Genitourinary 1Endocrine 1

Conditions

Wilms Tumor 1Sarcoma 1Rhabdomyosarcoma 1Retroperitoneal Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Desmoplastic Small Round Cell Tumor 1Brain Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Cytoreduction Surgical Procedures × Sarcoma × Clear all
NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Columbia University

Phase 1 Completed
22 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00436657 2012-04-02

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
10 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicSarcoma

Adenocarcinoma, Gastrointestinal Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Peritoneal Neoplasms, Retroperitoneal Neoplasms, Rhabdomyosarcoma, Sarcoma, Adrenocortical Carcinoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡